Janssen Diagnostics, LLC
14
0
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
21.4%
3 terminated/withdrawn out of 14 trials
75.0%
-11.6% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Molecular Studies and Clinical Correlations in Human Prostatic Disease
Role: collaborator
CEC Count Changes to Support GvHD Diagnosis.
Role: collaborator
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
Role: collaborator
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
Role: collaborator
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
Role: collaborator
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Role: lead
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
Role: collaborator
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Role: lead
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Role: lead
Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer
Role: lead
Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
Role: lead
Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
Role: collaborator
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
Role: collaborator
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Role: collaborator
All 14 trials loaded